SCHEMBL9268500

SCHEMBL9268500

CCCCCCCCc1cnc(-c2ccc(OCCCC)cc2)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 4/20 0.65
RAB9A P51151 7/20 0.65
NPC1 O15118 5/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
KDM4E B2RXH2 5/20 0.65
HSD17B10 Q99714 2/20 0.65
ALDH1A1 P00352 5/20 0.61
MAPT P10636 4/20 0.61
HPGD P15428 3/20 0.61
MEN1 O00255 2/20 0.61
USP2 O75604 2/20 0.61
KMT2A Q03164 2/20 0.61
GAA P10253 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.57
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
CYP3A4 P08684 3/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948263 1.00 RARB (0.65) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL14295767 1.00 RARB (0.65) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL13029249 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL2774683 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL9636338 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL10342131 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7910730 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL9436035 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7121080 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL9241350 0.98 RARB (0.63) RARBRAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170212088-A1 DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS PLATYPUS TECHNOLOGIES, LLC 2017-07-27 US disclosed
US-9575037-B2 Detection of gas-phase analytes using liquid crystals PLATYPUS TECHNOLOGIES, LLC (US) 2017-02-21 US disclosed
US-20160274084-A1 DETECTION OF VAPOR PHASE COMPOUNDS BY CHANGES IN PHYSICAL PROPERTIES OF A LIQUID CRYSTAL PLATYPUS TECHNOLOGIES, LLC 2016-09-22 US disclosed
US-9341576-B2 Detection of vapor phase compounds by changes in physical properties of a liquid crystal PLATYPUS TECHNOLOGIES, LLC (US) 2016-05-17 US disclosed
US-20160018371-A1 DETECTION OF GAS-PHASE ANALYTES USING LIQUID CRYSTALS PLATYPUS TECHNOLOGIES, LLC 2016-01-21 US disclosed
US-9103794-B2 Substrates, devices, and methods for quantitative liquid crystal assays PLATYPUS TECHNOLOGIES LLC (US) 2015-08-11 US disclosed
US-20140356970-A1 Liquid crystal devices with mixed anion metal salts NATIONAL SCIENCE FOUNDATION 2014-12-04 US disclosed
US-20140313468-A1 LIQUID CRYSTAL DISPLAY ELEMENT DIC CORPORATION (JP) 2014-10-23 US disclosed
US-8512820-B2 Organic ionic phenylpyrimidine compounds and displays formed thereof CITIZEN FINETECH MIYOTA CO., LTD. (JP) 2013-08-20 US disclosed
US-20120319044-A1 ORGANIC IONIC PHENYLPYRIMIDINE COMPOUNDS AND DISPLAYS FORMED THEREOF CITIZEN FINEDEVICE CO., LTD. (JP) 2012-12-20 US disclosed
US-20120288951-A1 DETECTION OF VAPOR PHASE COMPOUNDS BY CHANGES IN PHYSICAL PROPERTIES OF A LIQUID CRYSTAL PLATYPUS TECHNOLOGIES, LLC (US) 2012-11-15 US disclosed
US-20120135450-A1 SUBSTRATES, DEVICES, AND METHODS FOR QUANTITATIVE LIQUID CRYSTAL ASSAYS PLATYPUS TECHNOLOGIES, LLC (US) 2012-05-31 US disclosed
US-7795007-B2 contacting sample with a peptide attachment surface to create a peptidized surface, contacting the peptidized surface with a recognition reagent that selectively binds or forms a complex with the post-translationally modified peptide to provide an incubated surface, contacting a liquid crystal WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2010-09-14 US disclosed
US-20080268546-A1 DETECTION OF DNA HYBRIDIZATION ON SURFACES WISCONSIN ALUMNI RESEARCH FOUNDATION 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120319044-A1 ORGANIC IONIC PHENYLPYRIMIDINE COMPOUNDS AND DISPLAYS FORMED THEREOF PNP, PNPO, TYMP RARB 1775/4885RAB9A 4681/4885NPC1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.